Business

Definitive Healthcare Announces Pricing of Follow-On Offering of 11,000,000 Shares of Class A Common Stock

FRAMINGHAM, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare

articleDefinitive Healthcare Corp.November 17, 20215/company/definitive-healthcare-corp/news/definitive-healthcare-announces-pricing-of-follow-on-offering-of-11000000-shares-of-class-a-common-stock
Definitive Healthcare Announces Pricing of Follow-On Offering of 11,000,000 Shares of Class A Common Stock

About this update from Definitive Healthcare Corp.

[{"type":"text","content":"FRAMINGHAM, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the pricing of an underwritten public offering of 11,000,000 shares of its Class A common stock at a price to the public of $36.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 22, 2021, subject to the satisfaction of customary closing conditions. Definitive Healthcare intends to use the net proceeds from the proposed offering (a) for acquisitions and general corporate purposes, including purchasing 7,000,000 newly issued limited liability interests from its subsidiary AIDH TopCo, LLC, and (b) to repurchase an aggregate of 2,233,238 shares of Class A common stock and purchase 1,766,762 limited liability interests in AIDH TopCo, LLC from existing holders in a “synthetic secondary” transaction. In the event the underwriters exercise their option to purchase additional shares, Definitive Healthcare will use the net proceeds to repurchase additional shares of Class A common stock and purchase limited liability interests in AIDH TopCo, LLC from existing holders. Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead joint book-running managers and representatives of the underwriters for the proposed offering. Morgan Stanley & Co. LLC and Barclays Capital Inc. are acting as joint book-running managers and are also representatives of the underwriters for the proposed offering. Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. are acting as book-runners for the proposed offering. Canaccord Genuity LLC, Raymond James & Associates, Inc., Stifel, Nicolaus & Company, Incorporated, Drexel Hamilton, LLC and Loop Capital Markets are acting as co-managers. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained from the Securities and Exchange Commission (“SEC”) at www.sec.gov, and copies of the final prospectus may be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at p...

More updates from Definitive Healthcare Corp.